Does genetically guided antidepressant prescribing improve outcomes in depression?

Active, not recruiting

• Conditions: Major Depression; Mental Health - Depression

• Registration Number: ACTRN12613001135707
• Lead Sponsor: Dr Ajeet Singh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Principal Diagnosis Major Depression
Requires antidepressant treatment clinically

Exclusion Criteria

Pregnant or Breastfeeding
Conditions where antidepressants contra-indicated
Unable to give informed valid consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Remission from major depression, a score of 7 or less on the 17-item Hamilton Depression Rating Scale[12 weeks]

Secondary Outcome Measures

Name	Time	Method
Medication Tolerability. This is assessed by patient report of side effect to their prescriber, and if the side effects is so bothersome to the patient that the prescriber reduced the dose or ceases the antidepressant this will be noted as a medication tolerability problem. Transit or persisting side effects not so bothersome to lead to dose reduction or cessation will not be considered a clinically relevant tolerability issues.[12wks]